New Potential Targets of Glucagon-Like Peptide 1 Receptor Agonists in Pancreatic β-Cells and Hepatocytes.
Won Young LeePublished in: Endocrinology and metabolism (Seoul, Korea) (2017)
It is well known that both insulin resistance and decreased insulin secretory capacity are important factors in the pathogenesis of type 2 diabetes mellitus (T2DM). In addition to genetic factors, obesity and lipotoxicity can increase the risk of T2DM. Glucagon-like peptide 1 (GLP-1) receptor agonists are novel antidiabetic drugs with multiple effects. They can stimulate glucose-dependent insulin secretion, inhibit postprandial glucagon release, delay gastric emptying, and induce pancreatic β-cell proliferation. They can also reduce the weight of patients with T2DM and relieve lipotoxicity at the cellular level. Many intracellular targets of GLP-1 have been found, but more remain to be identified. Elucidating these targets could be a basis for developing new potential drugs. My colleagues and I have investigated new targets of GLP-1, with a particular focus on pancreatic β-cell lines and hepatic cell lines. Herein, I summarize the recent work from my laboratory, with profound gratitude for receiving the prestigious 2016 Namgok Award.
Keyphrases
- insulin resistance
- type diabetes
- glycemic control
- cell proliferation
- metabolic syndrome
- weight loss
- blood glucose
- induced apoptosis
- adipose tissue
- physical activity
- body mass index
- high fat diet
- weight gain
- cell cycle arrest
- cell cycle
- skeletal muscle
- gene expression
- cell death
- mass spectrometry
- climate change
- autism spectrum disorder
- endoplasmic reticulum stress
- risk assessment
- pi k akt